<table>
<thead>
<tr>
<th>Body System: <strong>Psychogenic</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Session Topic:</strong> Adult Depressive Disorder Updates</td>
<td></td>
</tr>
<tr>
<td><strong>Faculty Expertise Required</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Educational Format</strong></td>
<td></td>
</tr>
<tr>
<td>REQUIRED</td>
<td>Interactive Lecture</td>
</tr>
<tr>
<td>OPTIONAL</td>
<td>Problem-Based Learning (PBL)</td>
</tr>
<tr>
<td><strong>Professional Practice Gap</strong></td>
<td><strong>Learning Objective(s) that will close the gap and meet the need</strong></td>
</tr>
<tr>
<td>• There have been significant changes between the DSM-IV and the DSM-V with regard to the diagnosis of depressive disorders</td>
<td>1. Utilize appropriate diagnostic criteria to evaluate and screen patients for depression, mood disorders, and suicide risk.</td>
</tr>
<tr>
<td>• Physicians frequently face many barriers to depression guideline implementation</td>
<td>2. Know pharmacotherapy options for treating depression, and contraindications for certain classes of medications.</td>
</tr>
<tr>
<td>• Electronic Health Records (EHR) and PHQ data are frequently not used to optimize depression management, or to document suicidal ideation</td>
<td>3. Recognize the risks associated with certain drugs used to treat depression and mood disorders, and know which carry REMS and black box warnings about suicide.</td>
</tr>
<tr>
<td>• There is often a lack of knowledge about medication-related side effects of antidepressants, contributing to patient non-adherence</td>
<td>4. Coordinate care for patients who require referral to sub-specialists or admission to hospitals for suicide prevention.</td>
</tr>
<tr>
<td>• Several antidepressants have FDA-required Risk Evaluation and Mitigation Strategies (REMS)</td>
<td>5. Devise collaborative treatment plans for depression that take into account severity, suicidality, developmental stage, and environmental and social factors.</td>
</tr>
<tr>
<td>• Suboptimal levels of recognition and treatment</td>
<td></td>
</tr>
</tbody>
</table>
are due to a variety of physician, health system, and patient factors

- Access to psychiatry is limited in many communities and diagnosis and treatment of depression often falls to family physicians

<table>
<thead>
<tr>
<th>ACGME Core Competencies Addressed (select all that apply)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X Medical Knowledge</td>
</tr>
<tr>
<td>X Interpersonal and Communication Skills</td>
</tr>
<tr>
<td>Professionalism</td>
</tr>
</tbody>
</table>

**Faculty Instructional Goals**

Faculty play a vital role in assisting the AAFP to achieve its mission by providing high-quality, innovative education for physicians, residents and medical students that will encompass the art, science, evidence and socio-economics of family medicine and to support the pursuit of lifelong learning. By achieving the instructional goals provided, faculty will facilitate the application of new knowledge and skills gained by learners to practice, so that they may optimize care provided to their patients.

- Provide up to 3 evidence-based recommended practice changes that can be immediately implemented, at the conclusion of the session; including SORT taxonomy & reference citations
- Facilitate learner engagement during the session
- Address related practice barriers to foster optimal patient management
- Provide recommended journal resources and tools, during the session, from the American Family Physician (AFP), Family Practice Management (FPM), and Familydoctor.org patient resources; those listed in the References section below are a good place to start
  - Visit [http://www.aafp.org/journals](http://www.aafp.org/journals) for additional resources
  - Visit [http://familydoctor.org](http://familydoctor.org) for patient education and resources
- Provide recommendations regarding appropriate diagnostic criteria to evaluate and screen patients for depression, mood disorders, and suicide risk.
- Provide evidence-based recommendations for pharmacotherapy options for treating depression, and contraindications for certain classes of medications.
- Provide strategies for recognizing the risks associated with certain drugs used to treat depression and mood disorders, and know which carry REMS and black box warnings about suicide.
- Provide recommendations for coordinating care for patients who require referral to sub-specialists or admission to hospitals for suicide prevention.
- Provide recommendations for devising collaborative treatment plans for depression that take into account severity, suicidality, developmental stage, and environmental and social factors. and provide recommendations to utilize appropriate diagnostic criteria to evaluate and screen patients for depression, mood disorders, and suicide risk.
- Provide strategies and resources to coordinate care for patients who require referral to sub-specialists or admission to hospitals for suicide prevention.
• Provide an overview of newly available treatments, including efficacy, safety, contraindications, and cost/benefit relative to existing treatments.
• Provide recommendations to devise collaborative treatment plans for depression that take into account severity, suicidality, developmental stage, and environmental and social factors.
• Provide an overview of relevant changes in diagnosis between the DSM-IV and the DSM-V.
• Provide an overview of current guidelines for treatment, including updates on the safety and efficacy of pharmacologic therapies; also, including strategies for implementing cognitive behavioral concepts.

Needs Assessment
There are approximately 8 million ambulatory office visits per year where the primary diagnosis is depression, and 395,000 discharges from hospital inpatient care per year.1 In a given year, nearly 21 million U.S. adults (about 9.5% of the population) have a mood disorder, which includes major depressive disorder, dysthymic disorder and bipolar disorder. Many depressive disorders co-occur with anxiety disorders (such as panic disorder, obsessive-compulsive disorder and post-traumatic stress disorder) and substance abuse. The burden of mental illness is significant for many Americans; it is estimated that nearly 45% of those who have a diagnosable mental disorder meet the criteria for two or more disorders.2

Practice Gaps
Data from a recent American Academy of Family Physicians (AAFP) CME Needs Assessment survey indicate that family physicians have statistically significant and meaningful gaps in the medical skill necessary to provide optimal care and management of depression and suicide.3 More specifically, CME outcomes data from 2012-2014, and 2016 AAFP FMX (formerly Assembly) sessions on Mood Disorders, Depression, and Bipolar Disorders sessions suggest that physicians have knowledge and practice gaps with regard to standardized clinical monitoring and follow-up; consistent use of patient health questionnaire (e.g. PHQ2) and other screening tools; screening for comorbid conditions; latest evidence-based recommendations for use of pharmacologic treatments; being aware that depression is underdiagnosed; and efficiently managing depression within the time frame of a typical office visit.4-7

A review of the literature validates these and other practice gaps with regard to diagnosing and managing depression, summarized as follows:8-15
• There have been significant changes between the DSM-IV and the DSM-V with regard to the diagnosis of depressive disorders
• Physicians frequently face many barriers to depression guideline implementation
• Electronic Health Records (EHR) and PHQ data are frequently not used to optimize depression management; EHR's are underutilized to document/track suicidal ideation
• There is often a lack of knowledge about medication-related side effects of antidepressants, contributing to patient non-adherence
• Several antidepressants have FDA-required Risk Evaluation and Mitigation Strategies (REMS)
• Suboptimal levels of recognition and treatment are due to a variety of physician, health system, and patient factors
U.S. Food and Drug Administration boxed warning has been issued because of increased risk of suicidality in adolescents and young adults in the early months after starting SSRI therapy.

Physicians may improve their care of patients with depression by engaging in continuing medical education that provides practical integration of current evidence-based guidelines and recommendations into their standards of care, including, but not limited to the following:

- Selective serotonin reuptake inhibitors are more likely than placebo to produce depression remission in the primary care population.
- Serotonin-norepinephrine reuptake inhibitors are slightly more likely than selective serotonin reuptake inhibitors to improve depression symptoms, but they are associated with higher rates of adverse effects such as nausea and vomiting.
- For treatment-naive patients, all second-generation antidepressants are equally effective. Medication choice should be based on patient preferences, with adverse effect profiles, cost, and dosing frequency taken into consideration.
- Antidepressants are most effective in patients with severe depression.
- Preferred agents for older patients with depression include citalopram (Celexa), escitalopram (Lexapro), sertraline (Zoloft), mirtazapine (Remeron), venlafaxine, and bupropion (Wellbutrin). Because of higher rates of adverse effects in older adults, paroxetine (Paxil) and fluoxetine (Prozac) should generally be avoided.
- Treatment for a first episode of major depression should last at least four months. Patients with recurrent depression may benefit from prolonged treatment.
- The AAFP concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in adolescents, adults, and older adults in primary care.
- The AAFP recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow up. (2016)
- Don’t prescribe antipsychotic medications to patients for any indication without appropriate initial evaluation and appropriate ongoing monitoring.
- Don’t routinely prescribe two or more antipsychotic medications concurrently.
- Because there is no significant difference in performance among the different depression screening instruments, the most practical tool for the clinical setting should be used.
- The PHQ-2 is accurate for depression screening in adolescents, adults, and older adults.
- The PHQ-9 is a valid, quick screening instrument for depression that also can be used as a follow-up to a positive PHQ-2 result and to monitor treatment response.
- Depression screening in older adults can be accomplished with multiple instruments, including the PHQ-2, PHQ-9, and various Geriatric Depression Scales.
- Cognitive behavior therapy and interpersonal therapy should be used for the treatment of mild depression.
- Direct inquiry concerning suicidal ideation in patients with risk factors is associated with more effective treatment and management.
- Screening for depression, anxiety, and alcohol use helps to determine symptom severity in a patient with possible suicidal ideation.
- Use of suicide prevention contracts should generally be avoided.
- Treatment of suicidal ideation should include medications and psychological interventions.
- Current evidence does not support the routine use of vortioxetine in the treatment of depression.

Physicians can improve patient satisfaction with the referral process by using readily available strategies and tools such as, improving internal office communication, engaging patients in scheduling, facilitating the appointment, tracking referral results, analyzing data for improvement opportunities, and gathering patient feedback.23,24

While depression screening is not new for many family physicians, the United States Preventive Services Task Force (USPSTF) in January recommended expanding those screens to most adult patients, with a particular focus on women in the peripartum period.25 Clinical guidelines will often recommend behavioral counseling; however, many practices are not structured to offer these services effectively.26,27 Physicians should consider how to integrate behavioral health and psychiatry specialists into their practices.25,28 Physicians should also receive training to appropriately code for offering depression-related services.29

Physicians should also be kept up to date on new treatment therapies, changes to therapies, or warnings associated with existing therapies. Provide recommendations regarding new FDA approved medications for the treatment of depression; including safety, efficacy, tolerance, and cost considerations relative to currently available options. In 2015, the FDA approved Rexulti (brexpiprazole); Otsuka, for the treatment of depression and schizophrenia.30 Additionally, when started in the fall, extended-release bupropion, 300 mg once daily, is effective in preventing recurrent symptoms in high-risk adults with a history of SAD (number needed to treat [NNT] = 5), as well as those at lower risk (NNT = 8). Headaches, nausea, and insomnia may limit adherence to treatment.1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)31

These recommendations are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These recommendations are only one element in the complex process of improving the health of America. To be effective, the recommendations must be implemented. As such, physicians require continuing medical education to assist them with making decisions about specific clinical considerations.

Resources: Evidence-Based Practice Recommendations/Guidelines/Performance Measures
- Common Questions About the Pharmacologic Management of Depression in Adults17
- Screening for depression19
- Screening Your Adult Patients for Depression25
- Evaluation and treatment of the suicidal patient18
2018 AAFP FMX Needs Assessment

- AAFP Depression. Clinical Preventive Service Recommendation
- AAFP Suicide Screening. Clinical Preventive Service Recommendation
- Adding health education specialists to your practice
- Envisioning new roles for medical assistants: strategies from patient-centered medical homes
- The benefits of using care coordinators in primary care: a case study
- Engaging Patients in Collaborative Care Plans
- Medication adherence: we didn't ask and they didn't tell
- Encouraging patients to change unhealthy behaviors with motivational interviewing
- Integrating a behavioral health specialist into your practice
- Simple tools to increase patient satisfaction with the referral process
- Coding for depression without getting depressed
- FamilyDoctor.org. Depression (patient education)
- FamilyDoctor.org. Suicide (patient education)

References


30. CenterWatch. FDA Approved Drugs by Medical Condition. 2017;


